AUM: $496M · 13F, Q3 2026
| i | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasdaq: PBLS | Current | Pharmaceutical Preparations | COM | 5,266,697 | 0 | 0.0% | $170M | +$26M | 34.29% | $3.5B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: PHVS | Current | Pharmaceutical Preparations | COM | 4,458,977 | -184,453 | -4.0% | $141M | -$19M | 28.52% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Attovia Therapeutics, Inc. | Nasdaq: ATTO | Current | Biological Products, (No Diagnostic Substances) | COM | 4,181,366 | +4,181,366 | New | 9.16% | $72M | +$72M | 14.45% | $712M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Achieve Life Science Inc | QUIT | Current | COM | 5,914,720 | 0 | 0.0% | $48M | +$9M | 9.65% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |||
| Nasdaq: ALMS | Current | Pharmaceutical Preparations | COM | 4,191,408 | -337,000 | -7.4% | $31M | -$96M | 6.25% | $562M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: ALXO | Current | Pharmaceutical Preparations | COM | 12,884,638 | 0 | 0.0% | 9.97% | $18M | -$9M | 3.61% | $132M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Yarrow Bioscience, Inc. | Nasdaq: YARW | Current | Pharmaceutical Preparations | COM | 554,769 | +554,769 | New | 3.64% | $12M | +$12M | 2.52% | $217M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Lyell Immunopharma, Inc. | Nasdaq: LYEL | Current | Pharmaceutical Preparations | COM NEW | 337,697 | 0 | 0.0% | 1.37% | $3M | -$1M | 0.67% | $435M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 |
| LISATA THERAPEUTICS, INC. | Nasdaq: LSTA | Current | Pharmaceutical Preparations | COM | 156,460 | +156,460 | New | 1.45% | $0.2M | +$0.2M | 0.05% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Harmony Biosciences Holdings, Inc. | Nasdaq: HRMY | Exited | Pharmaceutical Preparations | COM | 0 | -472,194 | -100.0% | -$17M | $1.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | |||
| Acelyrin Inc | Exited | COM | 0 | -3,806,410 | -100.0% | -$9M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: ARTV | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -531,337 | -100.0% | -$3M | $189M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 |